FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma

FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma The detection of fibroblast growth factor receptor 3 (FGFR3) mutations in noninvasive bladder cancer mostly and a finding of FGFR3 overexpression in many invasive bladder cancers (BC) has created hope that targeted therapy against FGFR3 may have a major role in the treatment of BC. We aimed to evaluate immunohistochemically the expression of FGFR3 in urothelial carcinoma of the urinary bladder and correlate the results with various clinicopathologic variables to show the possible prognostic value of this marker. This study included 100 archived paraffin blocks of variable grades and stages of urothelial carcinoma. All cases were immunohistochemically stained with anti-FGFR3 antibody. FGFR3 immunostaining was detected in 88% (88/100) of urothelial carcinoma cases. A significant correlation was detected between FGFR3 expressions with the grade and depth of tumor invasion as 34% of low-grade cases (P = 0.002) and 26% of pTa-stage tumors (P = 0.02) showed high level of FGFR3 expression. Moreover, FGFR3 was significantly highly expressed in 34% of non-muscle-invasive tumors (P = 0.007), 34% of tumors with papillary growth pattern (P = 0.017), and lower-stage tumors (P = 0.00). In conclusion, high expression of FGFR3 in urothelial carcinomas with statistically significant relationships regarding its expression levels with parameters of favorable prognosis like low grade and pTa stage, presence of papillary architecture, and lower-stage urothelial carcinomas raised the probability that FGFR3 expression may have a role in early development of urothelial neoplasia. Further studies are required to investigate the applicability of FGFR3-targeted agents as an additional treatment regimen in patients with FGFR3 overexpression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Comparative Clinical Pathology Springer Journals

FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma

Loading next page...
 
/lp/springer_journal/fgfr3-a-marker-suggestive-of-favorable-prognosis-in-urothelial-2rsOiP90Xs
Publisher
Springer London
Copyright
Copyright © 2017 by Springer-Verlag London Ltd.
Subject
Medicine & Public Health; Pathology; Hematology; Oncology
eISSN
1618-565X
D.O.I.
10.1007/s00580-017-2510-7
Publisher site
See Article on Publisher Site

Abstract

The detection of fibroblast growth factor receptor 3 (FGFR3) mutations in noninvasive bladder cancer mostly and a finding of FGFR3 overexpression in many invasive bladder cancers (BC) has created hope that targeted therapy against FGFR3 may have a major role in the treatment of BC. We aimed to evaluate immunohistochemically the expression of FGFR3 in urothelial carcinoma of the urinary bladder and correlate the results with various clinicopathologic variables to show the possible prognostic value of this marker. This study included 100 archived paraffin blocks of variable grades and stages of urothelial carcinoma. All cases were immunohistochemically stained with anti-FGFR3 antibody. FGFR3 immunostaining was detected in 88% (88/100) of urothelial carcinoma cases. A significant correlation was detected between FGFR3 expressions with the grade and depth of tumor invasion as 34% of low-grade cases (P = 0.002) and 26% of pTa-stage tumors (P = 0.02) showed high level of FGFR3 expression. Moreover, FGFR3 was significantly highly expressed in 34% of non-muscle-invasive tumors (P = 0.007), 34% of tumors with papillary growth pattern (P = 0.017), and lower-stage tumors (P = 0.00). In conclusion, high expression of FGFR3 in urothelial carcinomas with statistically significant relationships regarding its expression levels with parameters of favorable prognosis like low grade and pTa stage, presence of papillary architecture, and lower-stage urothelial carcinomas raised the probability that FGFR3 expression may have a role in early development of urothelial neoplasia. Further studies are required to investigate the applicability of FGFR3-targeted agents as an additional treatment regimen in patients with FGFR3 overexpression.

Journal

Comparative Clinical PathologySpringer Journals

Published: Jul 9, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off